Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

Fact checked by Nick Blackmer In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH.Patients also saw improvements in weight, blood sugar, and insulin ...

Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

"Novo Nordisk continues to explore semaglutide across metabolic and cardiovascular health, including MASH, a condition with limited treatment options for patients and healthcare professionals ...